¼¼°è Æó¾Ï Áø´Ü ¹× ½ºÅ©¸®´× ½ÃÀå : °Ë»ç À¯Çüº°, ¾Ï À¯Çüº°, ÃÖÁ¾ »ç¿ëÀÚº°, Áö¿ªº°
Lung Cancer Diagnostic and Screening Market, By Test Type (Biomarkers Test Imaging Test (Computed Tomography scan, Positron Emission Tomography scan, Chest X-Ray, Others), Biopsy), By Cancer Type, By End User, By Geography
»óǰÄÚµå : 1378628
¸®¼­Ä¡»ç : Coherent Market Insights
¹ßÇàÀÏ : 2023³â 10¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹®
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,500 £Ü 6,511,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 7,000 £Ü 10,128,000
PDF (Multi User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 7¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 10,000 £Ü 14,469,000
PDF (Enterprise User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°è Æó¾Ï Áø´Ü ¹× ½ºÅ©¸®´× ½ÃÀåÀº 2023³â¿¡´Â 24¾ï 5,870¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ÃßÁ¤µÇ¸ç, ¿¹Ãø ±â°£Áß(2023-2030³â)ÀÇ CAGRÀº 10.1%°¡ µÉ Àü¸ÁÀÔ´Ï´Ù.

º¸°í ´ë»ó ¹üÀ§ º¸°í¼­ ¼¼ºÎÁ¤º¸
±âÁس⵵ 2022³â 2023³â ½ÃÀå ±Ô¸ð 24¾ï 5,870¸¸ ´Þ·¯
°ú°Å µ¥ÀÌÅÍ 2018-2021³â ¿¹Ãø ±â°£ 2023-2030³â
¿¹Ãø ±â°£ÀÇ CAGR 10.10% 2030³â ½ÃÀå ±Ô¸ð ¿¹Ãø 48¾ï 3,560¸¸ ´Þ·¯
±×¸² 1. Æó¾Ï Áø´Ü ¹× ½ºÅ©¸®´× ¼¼°è ½ÃÀå Á¡À¯À²(%), °Ë»ç À¯Çüº°, 2023³â
Lung Cancer Diagnostic and Screening Market-IMG1

Æó¾ÏÀº Æó¿¡¼­ ÅëÁ¦ ºÒ°¡´ÉÇÑ ¼¼Æ÷ ºÐ¿­·Î ÀÎÇÑ Áúº´ÀÔ´Ï´Ù. ¼¼Æ÷´Â Á¤»óÀûÀÎ ±â´ÉÀÇ ÀϺηΠºÐ¿­µÇ¾î ÀÚ½ÅÀÇ »çº»À» ´Ã¸³´Ï´Ù. ¼Õ»óµÈ ¼¼Æ÷ÀÇ ¹«Áú¼­ÇÑ ºÐ¿­Àº Á¶Á÷ Á¾¾çÀÌ µÇ°í °á±¹ Àå±â°¡ Á¦´ë·Î ÀÛµ¿ÇÏÁö ¾Ê½À´Ï´Ù. Æó¾ÏÀº Æó, ÀϹÝÀûÀ¸·Î ±âµµ(±â°üÁö ¶Ç´Â ¼¼±â°üÁö) ¶Ç´Â ÀÛÀº ±â³¶(ÆóÆ÷)À¸·Î ½ÃÀÛÇÕ´Ï´Ù. ´Ù¸¥ Àå¼Ò¿¡¼­ ½ÃÀÛÇÏ¿© Æó·Î ÀüÀÌÇÏ´Â ¾ÏÀº ÀϹÝÀûÀ¸·Î ¹ß»ýÇÑ Àå¼ÒÀÇ À̸§À» µû¼­ ¸í¸íµË´Ï´Ù. Æó¾Ï Ä¡·á¿¡´Â ¼ö¼ú, ¶óµð¿ÀÆÄ ¼ÒÀÛ¿ä¹ý, ¹æ»ç¼±¿ä¹ý, È­Çпä¹ý, Ç¥Àû ¾à¹°¿ä¹ý, ¸é¿ª¿ä¹ý µîÀÌ ÀÖ½À´Ï´Ù. ¾÷°èÀÇ ÁÖ¿ä ±â¾÷Àº ±â¼úÀûÀ¸·Î Áøº¸µÈ Á¦Ç° °³¹ß¿¡ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù. µû¶ó¼­ ÀÌ·¯ÇÑ ¼±ÁøÀûÀÎ Á¦Ç° ½ÃÀå¿¡ÀÇ µµÀÔÀº ¿¹Ãø±â°£¿¡ °ÉÃÄ ¼¼°è Æó¾Ï Áø´Ü ¹× ½ºÅ©¸®´× ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

½ÃÀå ¿ªÇÐ

¾÷°èÀÇ ÁÖ¿ä ±â¾÷Àº ´Ù¾çÇÑ ¼ö¼úÀ» À§ÇÑ ±â¼úÀûÀ¸·Î °í±Þ Àåºñ, ±â±¸, ½Ã½ºÅÛ °³¹ß¿¡ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù. µû¶ó¼­ ÀÌ·¯ÇÑ ¼±ÁøÀûÀÎ Á¦Ç° ½ÃÀå¿¡ÀÇ µµÀÔÀº ¿¹Ãø±â°£¿¡ °ÉÃÄ ¼¼°è Æó¾Ï Áø´Ü ¹× ½ºÅ©¸®´× ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, 2021³â 5¿ù, ºÐÀÚ Áø´Ü, ÀÀ¿ë°Ë»ç, Çмú ¹× Á¦¾à ¿¬±¸¿ë »ùÇà ¹× ºÐ¼® ±â¼úÀ» Á¦°øÇÏ´Â QIAGEN»ç´Â therascreen KRAS RGQ PCR Kit(therascreen KRAS Kit)°¡ Ä¡·á ´ë»óÀÌ µÉ ¼ö ÀÖ´Â ºñ¼Ò¼¼Æ÷ Æó¾Ï(NSCLC) ȯÀÚÀÇ µ¿Á¤À» Áö¿øÇÏ´Â ÄÄÆÐ´Ï¾ð Áø´Ü¾àÀ¸·Î¼­ ¹Ì±¹ ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎÀ» ÃëµæÇÑ °ÍÀ¸·Î ÄÄÆÐ´Ï¾ð Áø´Ü¾à(CDx)ÀÇ Ã»±¸ ¹üÀ§¸¦ È®´ëÇÑ ¹ß¸Å¸¦ ¹ßÇ¥Çß½À´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

¸ñÂ÷

Á¦1Àå Á¶»çÀÇ ¸ñÀû°ú ÀüÁ¦

Á¦2Àå ½ÃÀå Àü¸Á

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

Á¦4Àå ¼¼°è Æó¾Ï Áø´Ü ¹× ½ºÅ©¸®´× ½ÃÀå : ½ÅÇü Äڷγª ¹ÙÀÌ·¯½º °¨¿°Áõ(COVID-19)ÀÇ ¿µÇ⠺м®

Á¦5Àå ¼¼°è Æó¾Ï Áø´Ü ¹× ½ºÅ©¸®´× ½ÃÀå : °Ë»ç À¯Çüº°(2018-2030³â)

Á¦6Àå ¼¼°è Æó¾Ï Áø´Ü ¹× ½ºÅ©¸®´× ½ÃÀå : ¾Ï À¯Çüº°(2018-2030³â)

Á¦7Àå ¼¼°è Æó¾Ï Áø´Ü ¹× ½ºÅ©¸®´× ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°(2018-2030³â)

Á¦8Àå ¼¼°è Æó¾Ï Áø´Ü ¹× ½ºÅ©¸®´× ½ÃÀå : Áö¿ªº°(2018-2030³â)

Á¦9Àå °æÀï ±¸µµ

Á¦10Àå ¼½¼Ç

JHS
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The global lung cancer diagnostic and screening market is estimated to be valued at US$ 2,458.7 million in 2023 and is expected to exhibit a CAGR of 10.1% during the forecast period (2023-2030).

Report Coverage Report Details
Base Year: 2022 Market Size in 2023: US$ 2,458.7 Mn
Historical Data for: 2018 to 2021 Forecast Period: 2023 - 2030
Forecast Period 2023 to 2030 CAGR: 10.10% 2030 Value Projection: US$ 4,835.6 Mn
Figure 1. Global Lung Cancer Diagnostic and Screening Market Share (%), By Test Type, 2023
Lung Cancer Diagnostic and Screening Market - IMG1

Lung cancer is a disease caused by uncontrolled cell division in lungs. Cells divide and make more copies of themselves as part of their normal function. The uncontrolled division of damaged cells results in tissue tumors, which eventually prevent organs from functioning properly. Lung cancer start in the lungs, commonly in the airways (bronchi or bronchioles) or small air sacs (alveoli). Cancers that begin in another location and spread to the lungs are typically named after the location of their origin. Lung cancer treatments include surgery, radiofrequency ablation, radiation therapy, chemotherapy, targeted drug therapy, and immunotherapy. Key players in the industry are focusing on the development of technologically advanced products. Thus, the introduction of such advanced products into the market is expected to drive the growth of the global lung cancer diagnostic and screening market over the forecast period.

Market Dynamics

The key players in the industry are focusing on the development of technologically advanced equipment, instruments, and systems for various surgical procedures. Thus, the introduction of such advanced products in the market is expected to drive growth of the global lung cancer diagnostic and screening market over the forecast period. For instance, in May 2021, QIAGEN, a provider of sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research announced the launch of an expanded scope of companion diagnostic (CDx) claims for the therascreen KRAS RGQ PCR Kit (therascreen KRAS Kit) after it received U.S. regulatory approval as a companion diagnostic to aid in the identification of non-small cell lung cancer (NSCLC) patients that may be eligible for treatment.

Key features of the study:

Global Lung Cancer Diagnostic and Screening Market Detailed Segmentation:

Table of Contents

1. Research Objective and Assumption

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Lung Cancer Diagnostic and Screening Market - COVID-19 Impact Analysis

5. Global Lung Cancer Diagnostic and Screening Market, By Test Type, 2018-2030, (US$ Mn)

6. Global Lung Cancer Diagnostic and Screening Market, By Cancer Type, 2018-2030, (US$ Mn)

7. Global Lung Cancer Diagnostic and Screening Market, By End User, 2018-2030, (US$ Mn)

8. Global Lung Cancer Diagnostic and Screening Market, By Region, 2018-2030, (US$ Mn)

9. Competitive Landscape

10. Section

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â